Thank you.
mentioned, final study at Chicago. I'd to this David extra-strength the in Friday presented As top past of that with Jeuveau were ASDS share line like the results you
to of the it took frown and to study objective The across back a by baseline effect metric study doubled and after as of This assessed the been independent by scale investigator. was at was to X. being The primary Slide of the the is when patient glabellar single others the at looks treatment their long a return duration hyper-concentrated. how looking dose Jeuveau wrinkles studies. maximum that's the safety see when advantage used of and has
active at of when back units XX clinical the patient duration The Jeuveau was trial the label. X randomized was out their sites. carried controls, Slide with XX design was and BOTOX The study on returned units X The or baseline. X. the year X. Slide X to of of double-blind,
all registration to X-point moderate the with trials, line to the glabellar eligible rated As study. have scale be or for as on severe be either patients
the typical is were type patients patient Slide were primarily of the demographics and for women most themselves. severe, study, baseline late that When X. rated at both this X. it looking The in the the Slide of glabellar their severity, XXs. as by investigator subjects notable
itemized, to With whereas refer drug-related All events and include to adverse the headaches Jeuveau the there is drug-related being and safety, Below Slide study the the adverse X most common, adverse X by XX events to of table, the patients. no occurred There were that caused XX-unit line. drug. actual the have XX case eyelid in events in drug, X. events difference total, been events both the related regards events unrelated was between these there ptosis and in are with groups.
Slide X.
terms return were XX.X% was long with the back no of between look there baseline. to In as difference patient severity, how the to groups. at type study Nine. objective was to importantly, rated event adverse of of serious And no the events. the mild, their primary adverse
as severity line [indiscernible] investigator. Here's by assessed glabellar the
the return statistical or values And The also to and extra-strength XX-unit control shows previous their XX-unit XX-unit The baseline. and to demonstrated XX the superiority to months p arms. lasted arm ratios controls weeks the studies. plot provided X consistent the XX Jeuveau for Kaplan-Meier hazard with compared weeks,
XX. Slide glabellar duration XX. demonstrated response, the X-point results. a same Slide A by on definition, which is, improvement the scale, line meaningful clinically
was to assess way both controls. alternative the months, duration to the treatment scale. again, an As improvement global X use effect was Jeuveau superior weeks extra-strength XX.X or aesthetic [indiscernible] statistically assessment, is to
XX.
To responder, has none Here, or mild have lines. looking to we're be responder glabellar over at rates one a time.
visits X contributed a XX.X%. and see monthly lasted at rate since this decrease and of to and Looking XX dropouts. can And over high that, arm, no steady this for responders, in compared in-office longer patient visit, There and controls. a were responders between always the XX-unit the to time, one of burden to it graph, is the visits there's more the day percentage on day completion
it's mild treatment. glabellar Slide XX. responder use realize require none meaningful and measures not glabellar implications. definition we to Having When or clinically do lines, important mild repeat a is to the patients no lines ones these the of understand
However, groups since a the severity this responder can it as understand the using definition, between the when baseline it's results. important impact to
improvement presents respondent. sorry, consists if group severe need mostly X-point If treatment, that to a a need if only only to moderates group before mostly contrast, In In mostly has -- group contrast, the before then group responder. a mostly X-point need treatment, would they a improvement. the severes a become severes, a they become X-point of a improvement
to compares Jeuveau Slide frequently Daxi. XX. units of of asked XX how units We're XX
to from comparison trials even study, While here's respective their head-to-head same a an data direct requires attempt maintenance. the clinical a and overlay the
have results Daxxify study, a Jeuveau lasts improvement. a over none X as baseline Jeuveau due we a or patients Daxi also graph, assessed results the most required to that only to to combined each they required of XX-unit Sakura in this mild The the subject both most in Jeuveau Note investigator that the us XX-unit longer appear patients improvement by become X-point FDA-approved the results responder. time. the of compared label. contrast, X-point seen suggest their characteristics In as In
in the Jeuveau FDA XX-unit Daxxify patients from the a again, their similar X even demonstrates to Slide published label, required pattern, of XX. though Comparing results XX improvement. a as X-point units Jeuveau the most Sakura
subjects mandates studies. highest XX. a mild be X-grade of at the should This Using represents also achievement to and and score, efficacy X-point this composite success why is most grade baseline as from the investigator duration. defined suggests independently bar FDA definition, the all and of the composite as both or it concurrently. this endpoint The in X-point and the the and none of endpoint which primary the happened is used improvement as the toxicological a stringent responder FDA measure is agreeing it look
scores and responder Jeuveau's time XX their to the is that rates FDA units Based XX. in points on and for for measured this all are higher units at Sakura as X X Jeuveau. composite also from duration Daxxify The we XX Slide overlayered published suggests graph, Jeuveau longer compare graph Jeuveau label last X-point the Sakura
no active and multiple In seem differences drug-related be events adverse summary, there of demonstrated serious of XX being or adverse over duration mild XX.X% in Jeuveau compared events. XX. graded X as to controls, AD Slide to and weeks no with months metrics, extra-strength
turn it David. I'll back that, you, With to
